PDT Partners LLC Buys 38,599 Shares of Royalty Pharma plc (NASDAQ:RPRX)

PDT Partners LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 124.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 69,533 shares of the biopharmaceutical company’s stock after buying an additional 38,599 shares during the quarter. PDT Partners LLC’s holdings in Royalty Pharma were worth $1,774,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Keene & Associates Inc. raised its stake in Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 370 shares in the last quarter. National Bank of Canada FI boosted its position in shares of Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 371 shares during the period. Blue Trust Inc. boosted its holdings in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 376 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after purchasing an additional 388 shares during the period. Finally, Arizona State Retirement System grew its stake in Royalty Pharma by 0.5% in the 4th quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company’s stock worth $2,822,000 after acquiring an additional 537 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $42.50.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $32.71 on Wednesday. The firm’s fifty day simple moving average is $32.51 and its two-hundred day simple moving average is $29.50. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The firm has a market capitalization of $18.86 billion, a P/E ratio of 22.56, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma’s dividend payout ratio is presently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.